Literature DB >> 17338937

Pulmonary hypertension associated with chronic respiratory disease.

Reda E Girgis1, Stephen C Mathai.   

Abstract

Pulmonary hypertension (PH) has long been recognized as a complication of chronic respiratory disease. Recent studies have highlighted the adverse impact PH has on the clinical course of these conditions and have cast doubt on the role of hypoxia in their pathogenesis. Clinicians should carefully consider the possibility of PH during the diagnostic evaluation of chronic respiratory disorders. The usefulness of pharmacologic therapy directed toward PH remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338937     DOI: 10.1016/j.ccm.2006.11.006

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  12 in total

Review 1.  Multi-detector CT assessment in pulmonary hypertension: techniques, systematic approach to interpretation and key findings.

Authors:  Gareth Lewis; Edward T D Hoey; John H Reynolds; Arul Ganeshan; Jerome Ment
Journal:  Quant Imaging Med Surg       Date:  2015-06

2.  Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Amber Young; Dharshan Vummidi; Scott Visovatti; Kate Homer; Holly Wilhalme; Eric S White; Kevin Flaherty; Vallerie McLaughlin; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2019-06-18       Impact factor: 10.995

Review 3.  Right ventricular dysfunction in chronic lung disease.

Authors:  Todd M Kolb; Paul M Hassoun
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

4.  Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.

Authors:  R Saggar; D J Ross; R Saggar; D A Zisman; A Gregson; J P Lynch; M P Keane; S Samuel Weigt; A Ardehali; B Kubak; C Lai; D Elashoff; M C Fishbein; W D Wallace; J A Belperio
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

5.  JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.

Authors:  Marc A Sala; Cong Chen; Qiao Zhang; Hanh Chi Do-Umehara; Wenjiao Wu; Alexander V Misharin; Gregory B Waypa; Deyu Fang; G R Scott Budinger; Shuwen Liu; Navdeep S Chandel; Paul T Schumacker; Jacob I Sznajder; Jing Liu
Journal:  J Biol Chem       Date:  2017-11-08       Impact factor: 5.157

6.  Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension.

Authors:  Thomas A White; Tyra A Witt; Shuchong Pan; Cheryl S Mueske; Laurel S Kleppe; Eric W Holroyd; Hunter C Champion; Robert D Simari
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-31       Impact factor: 6.914

7.  Prediction and Subtyping of Hypertension from Pan-Tissue Transcriptomic and Genetic Analyses.

Authors:  Mahashweta Basu; Mahfuza Sharmin; Avinash Das; Nishanth Ulhas Nair; Kun Wang; Joo Sang Lee; Yen-Pei Christy Chang; Eytan Ruppin; Sridhar Hannenhalli
Journal:  Genetics       Date:  2017-09-12       Impact factor: 4.562

8.  Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.

Authors:  Christopher F Barnett; Eric J Bonura; Steven D Nathan; Shahzad Ahmad; Oksana A Shlobin; Kwabena Osei; Ari L Zaiman; Paul M Hassoun; David R Moller; Scott D Barnett; Reda E Girgis
Journal:  Chest       Date:  2008-12-31       Impact factor: 9.410

9.  Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes.

Authors:  Paul R Forfia; Anjali Vaidya; Susan E Wiegers
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

10.  COPD/emphysema: The vascular story.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Shiro Mizuno
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.